These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 12901232

  • 21. Targeting Hsp90 for the treatment of cancer.
    Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J.
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
    [Abstract] [Full Text] [Related]

  • 22. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY.
    Bioconjug Chem; 2007 Jul; 18(1):41-9. PubMed ID: 17226956
    [Abstract] [Full Text] [Related]

  • 23. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
    Sheldrake HM, Patterson LH.
    J Med Chem; 2014 Aug 14; 57(15):6301-15. PubMed ID: 24568695
    [Abstract] [Full Text] [Related]

  • 24. Inhibitors of integrins.
    Tucker GC.
    Curr Opin Pharmacol; 2002 Aug 14; 2(4):394-402. PubMed ID: 12127872
    [Abstract] [Full Text] [Related]

  • 25. Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy.
    Chaplin DJ, Hill SA.
    Curr Opin Investig Drugs; 2002 Sep 14; 3(9):1381-4. PubMed ID: 12498016
    [No Abstract] [Full Text] [Related]

  • 26. Intracellular trafficking of integrins in cancer cells.
    Onodera Y, Nam JM, Sabe H.
    Pharmacol Ther; 2013 Oct 14; 140(1):1-9. PubMed ID: 23711790
    [Abstract] [Full Text] [Related]

  • 27. Function and antagonism of beta3 integrins in the development of cancer therapy.
    Sheldrake HM, Patterson LH.
    Curr Cancer Drug Targets; 2009 Jun 14; 9(4):519-40. PubMed ID: 19519320
    [Abstract] [Full Text] [Related]

  • 28. Integrins as therapeutic targets.
    Goodman SL, Picard M.
    Trends Pharmacol Sci; 2012 Jul 14; 33(7):405-12. PubMed ID: 22633092
    [Abstract] [Full Text] [Related]

  • 29. Integrins: molecular targets in cancer therapy.
    Tucker GC.
    Curr Oncol Rep; 2006 Mar 14; 8(2):96-103. PubMed ID: 16507218
    [Abstract] [Full Text] [Related]

  • 30. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
    Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R.
    Future Oncol; 2011 Mar 14; 7(3):339-54. PubMed ID: 21417900
    [Abstract] [Full Text] [Related]

  • 31. Alpha-v integrins as therapeutic targets in oncology.
    Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA.
    Cancer Invest; 2007 Oct 14; 25(7):632-46. PubMed ID: 18027153
    [Abstract] [Full Text] [Related]

  • 32. Integrins as therapeutic targets: lessons and opportunities.
    Cox D, Brennan M, Moran N.
    Nat Rev Drug Discov; 2010 Oct 14; 9(10):804-20. PubMed ID: 20885411
    [Abstract] [Full Text] [Related]

  • 33. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles.
    Arosio D, Casagrande C, Manzoni L.
    Curr Med Chem; 2012 Oct 14; 19(19):3128-51. PubMed ID: 22612699
    [Abstract] [Full Text] [Related]

  • 34. An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities.
    Hatley RJD, Macdonald SJF, Slack RJ, Le J, Ludbrook SB, Lukey PT.
    Angew Chem Int Ed Engl; 2018 Mar 19; 57(13):3298-3321. PubMed ID: 28944552
    [Abstract] [Full Text] [Related]

  • 35. [Ligandomics--a tool for the development of targeted treatments].
    Porkka K, Laakkonen P.
    Duodecim; 2002 Mar 19; 118(11):1185-92. PubMed ID: 12239852
    [No Abstract] [Full Text] [Related]

  • 36. Small molecule alpha(v) integrin antagonists: novel anticancer agents.
    Kerr JS, Slee AM, Mousa SA.
    Expert Opin Investig Drugs; 2000 Jun 19; 9(6):1271-9. PubMed ID: 11060742
    [Abstract] [Full Text] [Related]

  • 37. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.
    Meyer A, Auernheimer J, Modlinger A, Kessler H.
    Curr Pharm Des; 2006 Jun 19; 12(22):2723-47. PubMed ID: 16918408
    [Abstract] [Full Text] [Related]

  • 38. Targeting integrins for the control of tumour angiogenesis.
    Akalu A, Cretu A, Brooks PC.
    Expert Opin Investig Drugs; 2005 Dec 19; 14(12):1475-86. PubMed ID: 16307488
    [Abstract] [Full Text] [Related]

  • 39. The alpha v integrin antagonists as novel anticancer agents: an update.
    Kerr JS, Slee AM, Mousa SA.
    Expert Opin Investig Drugs; 2002 Dec 19; 11(12):1765-74. PubMed ID: 12457436
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.